Assessment of the Effect of Filgotinib on the Pharmacokinetics of Atorvastatin, Pravastatin, and Rosuvastatin in Healthy Adult Participants-Reference-Cited by-同舟云学术

Assessment of the Effect of Filgotinib on the Pharmacokinetics of Atorvastatin, Pravastatin, and Rosuvastatin in Healthy Adult Participants

Published:2021-09 Issue:2 Volume:11 Page:235-245
ISSN:2160-763X
Container-title:Clinical Pharmacology in Drug Development
language:en
Short-container-title:Clinical Pharm in Drug Dev

Author:

Anderson Kacey¹,Nelson Cara H.¹,Gong Qi¹,Alani Muhsen¹²,Tarnowski Thomas¹,Othman Ahmed A.¹

Affiliation:

1. Gilead Sciences, Inc. Foster City California USA

2. Division of Rheumatology University of Washington Seattle Washington USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpdd.1015

Reference35 articles.

1. 2016 European Guidelines on cardiovascular disease prevention in clinical practice

2. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines;Grundy SM;Circulation,2019

3. Lipid management in rheumatoid arthritis: a position paper of the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology

5. Filgotinib: First Approval

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preventing and managing cardiovascular events in patients with inflammatory bowel diseases treated with small-molecule drugs, an international Delphi consensus;Digestive and Liver Disease;2024-08

2. Efficacy and Safety of Filgotinib in Rheumatoid Arthritis Patients Aged over and under 65 Years (ENANTIA-65);Journal of Personalized Medicine;2024-07-02

3. Bewertung von Wechselwirkungen und Dosierungsempfehlungen von synthetischen DMARDs – Evidenz- und konsensbasierte Empfehlungen auf Basis einer systematischen Literatursuche;Zeitschrift für Rheumatologie;2023-10-13

4. High hepatic and plasma exposures of atorvastatin in subjects harboring impaired cytochrome P450 3A4∗16 modeled after virtual administrations and possibly associated with statin intolerance found in the Japanese adverse drug event report database;Drug Metabolism and Pharmacokinetics;2023-04

5. JAK-inhibitors: clinical pharmacology and application perspectives;Reviews on Clinical Pharmacology and Drug Therapy;2023-03-06